Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients.

J Egypt Natl Canc Inst · 2022 · PMC13314244 · PMID 35871690

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

borderline significanceP = 0.06so close (0.05 < p ≤ 0.1)

The present results demonstrated their differential overexpression in refractory breast cancer patients, though revealing a borderline significance ( P = 0.06).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.